Last reviewed · How we verify
PMG Pharm Co., Ltd — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
3 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| LAYLA tablet | LAYLA tablet | marketed | SSRI | Serotonin transporter | Psychiatry | |
| CENATONE tablet | CENATONE tablet | marketed | ||||
| JOINS tablet | JOINS tablet | marketed | Orthopedics/Rheumatology | |||
| PG201 tablet | PG201 tablet | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes | |
| PK101-002 | PK101-002 | phase 3 | HIF-1α inhibitor | HIF-1α | Oncology | |
| PK101 | PK101 | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes |
Therapeutic area mix
- Diabetes · 2
- Oncology · 1
- Orthopedics/Rheumatology · 1
- Psychiatry · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Boryung Pharmaceutical Co., Ltd · 2 shared drug classes
- Qilu Pharmaceutical Co., Ltd. · 2 shared drug classes
- Astellas Pharma Inc · 2 shared drug classes
- Beni-Suef University · 2 shared drug classes
- EMS · 2 shared drug classes
- Pharmaceutical Project Solutions, Inc. · 2 shared drug classes
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 2 shared drug classes
- Sun Pharmaceutical Industries Limited · 2 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for PMG Pharm Co., Ltd:
- PMG Pharm Co., Ltd pipeline updates — RSS
- PMG Pharm Co., Ltd pipeline updates — Atom
- PMG Pharm Co., Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). PMG Pharm Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pmg-pharm-co-ltd. Accessed 2026-06-10.